XML 93 R80.htm IDEA: XBRL DOCUMENT v3.24.4
Note 15 - Stockholders' Equity (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Nov. 30, 2024
Aug. 31, 2024
Nov. 30, 2023
Aug. 31, 2023
Nov. 30, 2024
Nov. 30, 2023
May 31, 2024
Shares Authorized, Total (in shares) 1,208,000,000       1,208,000,000    
Common Stock, Shares Authorized (in shares) 1,198,000,000       1,198,000,000   1,198,000,000
Preferred Stock, Shares Authorized (in shares) 10,000,000       10,000,000   10,000,000
Common Stock, Shares, Issued (in shares) 929,257,945       929,257,945   831,925,373
Treasury Stock, Common, Shares (in shares) 3,682,609       3,682,609   0
Preferred Stock, Shares Issued (in shares) 0       0   0
Proceeds from Issuance of Common Stock         $ 111,517 $ 0  
Stock Issued During Period, Value, Settlement of Financing Liability $ 0     $ 8,146      
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)         6,869,485    
Share-Based Payment Arrangement, Expense $ 7,237   $ 8,201   $ 14,154 $ 16,458  
Common Stock, Shares, Outstanding (in shares) 929,257,945       929,257,945   831,925,373
Preferred Stock, Shares Outstanding (in shares) 0       0   0
Time-based Restricted Stock Units [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         13,346,266 11,588,537  
Performance-based Restricted Stock Units [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         0 7,566,146  
Restricted Stock Units (RSUs) [Member]              
Share-Based Payment Arrangement, Expense $ 7,237   $ 8,201   $ 14,154 $ 16,458  
Tilray Brands Inc MediPharm / HEXO Litigation Settlement [Member]              
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares)         13,217,588    
Stock Issued During Period, Value, Settlement of Financing Liability         $ 23,824    
Treasury Stock, Common [Member]              
Stock Issued During Period, Shares, New Issues (in shares) 0 0          
Stock Issued During Period, Shares, Settlement of Financing Liability (in shares) 0     0      
Stock Issued During Period, Value, Settlement of Financing Liability $ 0     $ 0      
Settlement of TLRY 27 Convertible Note With Share Issuance [Member]              
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature         $ 4,931    
Settlement of TLRY 27 Convertible Note With Share Issuance [Member] | Treasury Stock, Common [Member]              
Debt Conversion, Converted Instrument, Shares Issued (in shares)         3,682,609    
TLRY 27 [Member]              
Stock Issued During Period, Shares, For The Repayment of Convertible Debt (in shares)         10,034,635    
Debt Instrument, Repurchase Amount $ 16,500       $ 16,500   $ (0)
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature         $ 4,931    
At-the-Market Program [Member]              
Stock Issued During Period, Shares, New Issues (in shares)         67,210,864    
Proceeds from Issuance of Common Stock         $ 114,342    
Net Proceeds from Issuance of Common Stock         111,516    
Payments of Stock Issuance Costs         $ 2,826